Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer
Cancer Immunology, Immunotherapy · 2023-07 · 72 (7) · 2045-2056
DOI: 10.1007/s00262-023-03386-7 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 16.02.2023. Verfasst von Yao-Jun Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China. Hauptthemen laut MEDLINE: Cancer Vaccines, Colorectal Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wenzhou Major Science and Technology Special Project from Wenzhou Science and Technology Bureau, Public Benefit Technology Research Project of Zhejiang Science and Technology Department, Research Foundation of Academician Helin Workstation.
Abstract (Originalsprache)
Immunotherapy based on immune checkpoint inhibitors (ICIs) has provided revolutionary results in treating various cancers. However, its efficacy in colorectal cancer (CRC), especially in microsatellite stability-CRC, is limited. This study aimed to observe the efficacy of personalized neoantigen vaccine in treating MSS–CRC patients with recurrence or metastasis after surgery and chemotherapy. Candidate neoantigens were analyzed from whole-exome and RNA sequencing of tumor tissues. The safety and immune response were assessed through adverse events and ELISpot. The clinical response was evaluated by progression-free survival (PFS), imaging examination, clinical tumor marker detection, circulating tumor DNA (ctDNA) sequencing. Changes in health-related quality of life were measured by the FACT-C scale. A total of six MSS–CRC patients with recurrence or metastasis after surgery and chemotherapy were administered with personalized neoantigen vaccines. Neoantigen-specific immune response was observed in 66.67% of the vaccinated patients. Four patients remained progression-free up to the completion of clinical trial. They also had a significantly longer progression-free survival time than the other two patients without neoantigen-specific immune response (19 vs. 11 months). Changes in health-related quality of life improved for almost all patients after the vaccine treatment. Our results shown that personalized neoantigen vaccine therapy is likely to be a safe, feasible and effective strategy for MSS–CRC patients with postoperative recurrence or metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.
- Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, 312000, People's Republic of China.
- Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.
- Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.
- School of Basic Medicine, Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.
- Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China. bloooge@163.com.
Förderung
- Wenzhou Major Science and Technology Special Project from Wenzhou Science and Technology Bureau
- Public Benefit Technology Research Project of Zhejiang Science and Technology Department
- Research Foundation of Academician Helin Workstation
- project of Wenzhou science and Technology Bureau
- Key Research and Development Program of Zhejiang Province
Zitieren
APA
Yu, Y. J., Shan, N., Li, L. Y., Zhu, Y. S., Lin, L. M., Mao, C. C., Hu, T. T., Xue, X. Y., Su, X. P., Shen, X., & Cai, Z. Z. (2023). Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. Cancer Immunology, Immunotherapy, 72(7), 2045-2056. https://doi.org/10.1007/s00262-023-03386-7
Vancouver
Yu YJ, Shan N, Li LY, Zhu YS, Lin LM, Mao CC, et al. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. Cancer Immunology, Immunotherapy. 2023;72(7):2045-2056. doi:10.1007/s00262-023-03386-7
BibTeX
@article{Yu2023,
author = {Yu, Yao-Jun and Shan, Na and Li, Li-Yi and Zhu, Yue-Sheng and Lin, Li-Miao and Mao, Chen-Chen and Hu, Ting-Ting and Xue, Xiang-Yang and Su, Xiao-Ping and Shen, Xian and Cai, Zhen-Zhai},
title = {Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
volume = {72},
number = {7},
pages = {2045--2056},
doi = {10.1007/s00262-023-03386-7}
}
EUVIMED